Medications Development for the Treatment of Amphetamine and Amphetamine Like Related Disorders (R01) | Apply Online

Opportunity Summary:

This NIH grant opportunity (Funding Opportunity Number PA 07 333) is an R01 program announcement designed to push medications development forward for Amphetamine and Amphetamine-like Related Disorders (ARDs), with the strongest emphasis on methamphetamine abuse and methamphetamine dependence. The National Institute on Drug Abuse (NIDA) is looking for research that moves beyond basic interest and directly supports the identification, evaluation, and development of safe and effective pharmacological treatments. The announcement explicitly encourages both preclinical work (such as screening, mechanism studies, and candidate optimization) and clinical research (including early-stage and later-stage testing) aimed at producing real-world medication options for these disorders.

The scientific scope is defined using DSM-IV-TR language and covers a broad class of stimulant substances. It includes drugs with a substituted phenylethylamine structure such as amphetamine, dextroamphetamine, methamphetamine, and MDMA (3,4-methylenedioxymethamphetamine). It also extends to substances that are structurally different but produce similar amphetamine-like effects, including methylphenidate, certain appetite suppressants, and khat. The program announcement highlights that these substances are highly addictive central nervous system stimulants and that they are commonly used through multiple routes of administration, including injection, snorting, smoking, and oral ingestion. In practice, this framing signals that proposed medications and study designs can target a range of stimulant-related disorders, while still aligning with the core priority of methamphetamine.

A major rationale for the announcement is the continuing public health impact of methamphetamine in the United States. NIDA notes that prevalence and surveillance data are most readily available for methamphetamine abuse and dependence and indicate persistent, widespread harm across essentially all population segments. The opportunity also underscores why methamphetamine is especially challenging from a policy and health standpoint: it can be produced relatively easily in clandestine laboratories using store-bought materials, and it has been described as the most prevalent synthetic drug manufactured in the U.S. The announcement points to how these factors have contributed to the drug's spread beyond its earlier concentration in the western states to nearly every major metropolitan area, driven by low cost, high availability, and strong addictive potential.

The gap this grant is intended to address is straightforward: there were no effective pharmacological treatments available for ARDs at the time of the announcement, and NIDA describes the overall research base on medication identification and development, as well as on the health effects of chronic abuse, as limited. The core message is that the agency wants more and better-targeted research that can translate into clinically meaningful medications, and it is using the R01 mechanism to support substantial, multi-year projects that can generate strong preclinical packages, credible clinical evidence, or both.

Administratively, this is a discretionary grant opportunity under the NIH, with the activity aligned to CFDA 93.279 (Drug Abuse and Addiction Research Programs). It does not require cost sharing or matching. The posting date listed is March 22, 2007, with multiple receipt dates (rather than a single deadline), meaning applications could be submitted across several cycles as specified in the full announcement. The opportunity ultimately archived on June 7, 2010, which matters for anyone looking at it historically versus seeking an active funding mechanism today.

Eligibility is broad and inclusive, spanning many public and private entity types. Eligible applicants include state and local governments (state governments, county governments, city or township governments), school districts, special district governments, public and state-controlled institutions of higher education, and private institutions of higher education. Nonprofits are eligible whether they have 501(c)(3) status or not, and both small businesses and for-profit organizations (other than small businesses) are listed as eligible. Tribal entities are included (federally recognized tribal governments as well as other tribal organizations), along with public housing authorities/Indian housing authorities. The announcement also states that foreign institutions may apply, eligible federal agencies may apply, and faith-based or community-based organizations may apply, which is a useful signal that NIH is prioritizing scientific merit and capacity over a narrow institutional profile.

For full details, applicants were directed to the NIH program announcement page (http://grants.nih.gov/grants/guide/pa-files/PA-07-333.html). The listed contact support is the NIH Office of Extramural Research (OER) webmaster for technical access or linking issues (FBOWebmaster@OD.NIH.GOV).

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Medications Development for the Treatment of Amphetamine and Amphetamine Like Related Disorders (R21)

Previous opportunity: Development of Assays for High Throughput Drug Screening (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 07 333

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 07 333) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 333", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.